CancerTEX10 targeting improves oxaliplatin sensitivity in CRCColorectal cancer (CRC) is the second leading cause of cancer-related deaths globally. Oxaliplatin-based therapy remains the standard-of-care for advanced CRC, but is characterized by a drop in sensitivity, where patients develop resistance that leads to treatment failure and a 5-year survival rate of <10.5%. Understanding the molecular basis behind oxaliplatin resistance is crucial for improving patient outcomes.